Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)

✍ Scribed by Sikov, William M. (author);Berry, Donald A. (author);Perou, Charles M. (author);Singh, Baljit (author);Cirrincione, Constance T. (author);Tolaney, Sara M. (author);Kuzma, Charles S. (author);Pluard, Timothy J. (author);Somlo, George (author);Port, Elisa R. (author);Golshan, Mehra (author);Bellon, Jennifer R. (author);Collyar, Deborah (author);Hahn, Olwen M. (author);Carey, Lisa A. (author);Hudis, Clifford A. (author);Winer, Eric P. (author)

• Book ID: 125854930
• Publisher: American Society of Clinical Oncology
• Year: 2015
• Tongue: English
• Weight: 288 KB
• Volume: 33
• Category: Article
• ISSN: 0732-183X
• DOI: 10.1200/JCO.2014.57.0572